Johnson & Johnson Medical Executive Announces Departure Amid Orthopedics Spin-off
Johnson & Johnson
Medical Device R&D and Manufacturer
Noramco
Active Pharmaceutical Ingredient (API) Developer and Manufacturer
DePuy Synthes
Orthopedic Product Developer
Source: Medical Device Business Review
Yesterday, Leslie Storms, President of Johnson & Johnson Medical Technologies' U.S. Orthopedics division, announced that she will step down this month, concluding an 18-year career with the company.
She announced the decision publicly via LinkedIn and expressed gratitude towards the company.
Storms wrote, "I am incredibly fortunate to work alongside exceptional leaders and a talented team who are passionate about their work because they always keep the end beneficiaries in mind—the patients." She further added, "Johnson & Johnson has not only provided me with room to grow but also encouraged me to think from different perspectives, empowered me to leverage my expertise, contribute fresh insights, and supported me and my family in every way."
Leslie Storms
According to her LinkedIn profile, Storms began her career at Noramco, a pharmaceutical ingredients division under Johnson & Johnson, where she served as the Global Vice President of Sales and Marketing. This division was later sold in 2016. In 2013, she transferred to Janssen Pharmaceuticals, taking on the role of Senior Marketing Director for Central Nervous System therapies. She then joined Johnson & Johnson Vision, holding various Vice President positions over a span of three years. Afterward, she transitioned to the medical technology sector, serving as Vice President of Surgical Sales, President of Surgical Sales, and in 2023, assumed the role of President of the Orthopedics business.
Notably, this personnel change comes as Johnson & Johnson advances its plan to spin off the DePuy Synthes orthopedics business.
On October 14, 2025, Johnson & Johnson announcedPlans to spin off its orthopedics business into an independent company within the next 18 to 24 months., marking the second major spin-off for the company within two years as it focuses on high-growth healthcare sectors.
Johnson & Johnson CFO Joe Wolk(Joe Wolk) said,The separation process is already underway., but the company does not expect to provide further significant updates on the transaction until mid-2026. The company is currently exploring various spin-off options, primarily focusing on a tax-free spin-off, while remaining open to other alternatives.
Johnson & Johnson's orthopedics division, which produces hip, knee, and shoulder implants, surgical instruments, and other products, generated approximately $9.2 billion in revenue last year, accounting for about 10% of total revenue.After the split, the new company will be named DePuy Synthes and led by industry veteran Namal Nawana.
The content of this article is for reference only and does not constitute investment advice. Readers are expected to effectively distinguish.If any platform reprints this article, it must take responsibility for the content of the article. Medical Device Business Review is not responsible for the impact of secondary dissemination caused by reprints.
Click the image to go directly to the purchase
If you find the content rewarding, welcomeStarred、Like、Forward！
Your support is our greatest motivation.
